Welcome to LookChem.com Sign In|Join Free

CAS

  • or
(S)-1-(4-fluorophenyl)-3-iodopropan-1-ol is an organic compound characterized by a molecular formula of C9H10FIO. It features a chiral center with the (S) configuration, where a fluorophenyl group is attached to a 3-iodopropan-1-ol moiety. This unique structure and reactivity make it a valuable compound in the fields of medicinal chemistry and pharmaceutical research.

926657-23-0

Post Buying Request

926657-23-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

926657-23-0 Usage

Uses

Used in Medicinal Chemistry and Pharmaceutical Research:
(S)-1-(4-fluorophenyl)-3-iodopropan-1-ol is utilized as a potential building block for the synthesis of biologically active molecules. Its distinctive structure and reactivity contribute to the development of new drugs and organic synthesis strategies, making it a valuable tool in these fields.
Used in Metal-Catalyzed Reactions:
(S)-1-(4-fluorophenyl)-3-iodopropan-1-ol has demonstrated potential as a ligand in metal-catalyzed reactions. Its unique properties allow it to enhance the efficiency and selectivity of these reactions, further expanding its applications in the realm of organic chemistry.

Check Digit Verification of cas no

The CAS Registry Mumber 926657-23-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,6,6,5 and 7 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 926657-23:
(8*9)+(7*2)+(6*6)+(5*6)+(4*5)+(3*7)+(2*2)+(1*3)=200
200 % 10 = 0
So 926657-23-0 is a valid CAS Registry Number.
InChI:InChI=1/C9H10FIO/c10-8-3-1-7(2-4-8)9(12)5-6-11/h1-4,9,12H,5-6H2/t9-/m0/s1

926657-23-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name (1S)-1-(4-fluorophenyl)-3-iodopropan-1-ol

1.2 Other means of identification

Product number -
Other names S01-0660

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:926657-23-0 SDS

926657-23-0Relevant articles and documents

Dynamic kinetic resolution: Asymmetrie transfer hydrogenation of α-alkyl-substituted β-ketoamides

Limanto, John,Krska, Shane W.,Dorner, Benjamin T.,Vazquez, Enrique,Yoshikawa, Naoki,Tan, Lushi

supporting information; experimental part, p. 512 - 515 (2010/05/02)

[Chemical equation presented] Dynamic kinetic resolution (deracemization) of various a-alkyl-substituted β-ketoamides 1 via asymmetric transfer hydrogenation proceeded efficiently to give the corresponding syn-β-hydroxy amides 3 in high diastereo- and enantioselectivities. Specifically, subjection of 1 to HCO2H and Et3N in the presence of 0.5-1 mol % of pentafluorobenzenesulfonyl-DPEN-Ru catalyst 2b at 30-40 °C in either PhCH3 or CH2Cl2 generated the syn-hydroxy product 3 selectively in 15-33:1 dr, 93-97% ee, and 75-88% isolated yields.

PROCESS FOR PREPARING AN ANTI-HYPERCHOLESTEROLEMIC COMPOUND

-

Page/Page column 26-27; 53, (2009/05/30)

The present invention relates to a process for preparing inhibitors of cholesterol absorption of Formula II: II and the pharmaceutically acceptable salts and esters thereof, employing a metal-catalyzed dynamic kinetic resolution (DKR) asymmetric transfer hydrogenation (ATH) reaction of racemic acyclic ?-ketoamide bearing a-substituted aliphatic side chain (Intermediate A) and subsequent cyclization of the resulting b-hydroxyamide product (Intermediate B), followed by a synthesis involving two consecutive cross-coupling reactions.

Ezetimibe analogs with a reorganized azetidinone ring: Design, synthesis, and evaluation of cholesterol absorption inhibitions

Xu, Xianxiu,Fu, Renzhong,Chen, Jin,Chen, Shengwu,Bai, Xu

, p. 101 - 104 (2007/10/03)

The underlying principle of drug design in this paper is that the maximum retention of the functional groups that exist in the marketed drug would provide a higher probability for comparable safety while the conformational changes in the newly created ana

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 926657-23-0